PortfoliosLab logoPortfoliosLab logo
Vor Biopharma Inc. (VOR)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US9290331084
CUSIP
929033108
IPO Date
Feb 5, 2021

Highlights

Market Cap
$176.11M
Enterprise Value
-$217.09M
EPS (TTM)
-$91.51
EBITDA (TTM)
-$371.64M
Year Range
$2.62 - $65.80
Target Price
$50.50
ROA (TTM)
-149.96%
ROE (TTM)
423.57%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Vor Biopharma Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Vor Biopharma Inc. (VOR) has returned 36.39% so far this year and 24.32% over the past 12 months.


Vor Biopharma Inc.

1D
21.36%
1M
15.54%
YTD
36.39%
6M
-63.38%
1Y
24.32%
3Y*
-45.06%
5Y*
-52.97%
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Feb 5, 2021, VOR's average daily return is -0.01%, while the average monthly return is +6.01%. At this rate, your investment would double in approximately 1.0 years.

Historically, 42% of months were positive and 58% were negative. The best month was Jun 2025 with a return of +710.4%, while the worst month was May 2025 at -70.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, VOR closed higher 43% of trading days. The best single day was Jun 25, 2025 with a return of +74.3%, while the worst single day was May 8, 2025 at -70.1%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-0.61%18.77%15.54%36.39%
202527.93%-23.94%-33.56%-5.35%-70.56%710.41%27.78%-4.83%23.65%-50.51%-65.45%57.02%-41.08%
20242.22%0.00%3.04%-27.43%-21.51%-25.93%-7.12%-5.88%-19.93%19.97%-0.93%33.41%-50.67%
2023-20.75%5.88%-3.58%-17.29%5.62%-34.26%-2.27%-17.22%-15.20%-13.68%1.09%21.62%-66.17%
2022-29.00%9.45%-33.11%-5.13%-26.53%18.05%-7.24%11.28%-22.42%20.85%-4.37%44.57%-42.77%
202119.89%-4.14%-34.62%-25.12%-11.61%-32.87%17.33%6.74%0.32%-26.64%0.69%-69.01%

Benchmark Metrics

Vor Biopharma Inc. has an annualized alpha of -16.17%, beta of 1.26, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since February 08, 2021.

  • This stock participated in 32.46% of S&P 500 Index downside but only -122.33% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-16.17%
Beta
1.26
0.03
Upside Capture
-122.33%
Downside Capture
32.46%

Return for Risk

Risk / Return Rank

VOR ranks 58 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.


VOR Risk / Return Rank: 5858
Overall Rank
VOR Sharpe Ratio Rank: 4545
Sharpe Ratio Rank
VOR Sortino Ratio Rank: 7676
Sortino Ratio Rank
VOR Omega Ratio Rank: 7878
Omega Ratio Rank
VOR Calmar Ratio Rank: 4646
Calmar Ratio Rank
VOR Martin Ratio Rank: 4444
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Vor Biopharma Inc. (VOR) and compare them to a chosen benchmark (S&P 500 Index).


VORBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.13

0.90

-0.77

Sortino ratio

Return per unit of downside risk

1.89

1.39

+0.51

Omega ratio

Gain probability vs. loss probability

1.27

1.21

+0.06

Calmar ratio

Return relative to maximum drawdown

0.21

1.40

-1.19

Martin ratio

Return relative to average drawdown

0.32

6.61

-6.29

Explore VOR risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Vor Biopharma Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Vor Biopharma Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vor Biopharma Inc. was 99.72%, occurring on May 9, 2025. The portfolio has not yet recovered.

The current Vor Biopharma Inc. drawdown is 98.35%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.72%Feb 26, 20211056May 9, 2025
-16.81%Feb 17, 20215Feb 23, 20211Feb 24, 20216
-1.99%Feb 11, 20211Feb 11, 20211Feb 12, 20212

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Vor Biopharma Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Vor Biopharma Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items